ABSTRACT: Using a mouse mutant that fractures spontaneously and dies at a very young age, we identified that a deletion of the GULO gene, which is involved in the synthesis of vitamin C, is the cause of impaired osteoblast differentiation, reduced bone formation, and development of spontaneous fractures.
INTRODUCTION
O STEOPOROSIS IS A DISEASE characterized by a loss of bone mass and strength, often resulting in bone fractures (most frequently of the hip, spine, and forearm) from even minor trauma. Such osteoporotic fractures are a significant cause of disability. Hip fracture alone is associated with a 15-25% excess mortality rate in the first year after fracture. (1) In addition, the direct medical cost associated with managing bone fractures was estimated to be in excess of 13 billion dollars in the United States in 1995 alone. (2) As the size of the world's population Ն50 years of age increases during the next several decades, it is likely that both the direct and indirect costs of such fractures will increase as well. (3) Therefore, successful efforts to reduce the number of osteoporotic fractures would lead to considerable savings in health care costs as well as improved health both in the United States and abroad.
A hallmark of osteoporosis is spontaneous fracture, and one of the most significant determinants of spontaneous fracture is low BMD. In women, BMD after the menopause is determined first by a peak BMD achieved by the early 20s, and subsequently by a rate of BMD loss after menopause. (4) Because genetics plays a large role in the variation in peak BMD found in different individuals, studies in the field of bone research focus primarily on identifying those genes involved in determining peak BMD. (5) Despite the identification of several potential candidate genes that may play a role in the development of peak BMD, there remain large gaps in our understanding of the molecular genetic mechanisms involved in the pathogenesis of osteoporosis.
To identify candidate genes that may be important in the development of osteoporosis, we studied a mutant mouse that develops spontaneous fractures at the very early age of 5-7 weeks. (6) In previous studies, it was found that these mutant mice homozygous for the spontaneous fracture (gene symbol: sfx) gene mutation appeared phenotypically normal until they were weaned at 21 days of age. Shortly thereafter, these sfx mice developed a number of irregularities, including an inability to maintain their normal pubertal growth, manifestation of both skeletal and hematocrit abnormalities, development of fractures, and finally premature death at ∼7-8 weeks of age. (6) Interestingly, many of the features of the sfx mouse resemble characteristics of scurvy syndrome. (7) (8) (9) (10) Mice normally synthesize their own ascorbic acid because of the presence of a key enzyme in ascorbic acid synthesis, l-gulono-lactone-␥-oxidase (GULO), that is present in the liver. (11) (12) (13) (14) (15) This enzyme catalyzes the terminal reaction converting l-gulono-␥-lactone to l-keto-gulono-␥-lactone, whereupon l-ascorbic acid is produced through isomerizations. (11) (12) (13) (14) (15) The GULO enzyme is found in the liver of higher vertebrate species (pigs, rats, mice) and in the kidney of lower vertebrate species (birds, turtles, and some fish), but not in humans, primates, or guinea pigs. (11) (12) (13) (14) (15) Because mice can synthesize ascorbic acid, it is not considered an essential dietary component for this species, and therefore vitamin C is not usually added to mouse chow. In contrast, humans depend entirely on dietary supplementation for their vitamin C.
The sfx gene, already known to be located in chromosome 14 , has now been identified as gulonolactone oxidase (GULO), which is involved in the synthesis of ascorbic acid. (13, 15) The findings of this study provide the first genetic evidence that ascorbic acid deficiency in sfx mice contributes to impaired bone formation and spontaneous fractures and that treatment of sfx mice with ascorbic acid reverses the mutant phenotype. Our findings also show that impairment in differentiation of osteoblasts contributes to bone formation deficiency in sfx mice and that in vitro treatment of bone marrow-derived stromal cells from sfx mice with ascorbic acid corrects the deficiency in osteoblast differentiation.
MATERIALS AND METHODS

Materials
␣-MEM was purchased from Gibco (Invitrogen, Grand Island, NY, USA). Calf serum was purchased from Atlanta Biologicals (Norcross, GA, USA). DMEM was purchased from Cellgrow (Media Tech, Herndon, VA, USA). Tissue culture dishes were purchased from Corning (Corning, NY, USA). Ascorbic acid, ascorbic acid 2-phosphate, ␤-glycerophosphate, and alizarin red were purchased from Sigma Chemicals (St Louis, MO, USA). All other chemicals were purchased from Sigma Chemicals or Fisher Scientific (Tustin, CA, USA).
Mice
The sfx phenotype first appeared in a BALB/cBy inbred strain and was discovered in the mouse mutant resource of the Jackson Laboratory. (6) Breeding pairs of sfx mice were obtained from the Jackson Laboratory and bred to produce homozygous and corresponding control mice at the Jerry L. Pettis Memorial VA Medical Center animal facility. The animals were fed with either a Harlan Teklad S-2335 mouse breeder diet -7004 (during breeding) or with a Harlan Teklad 4% mouse/rat diet-7001 (Harlan, Indianapolis, IN, USA). Neither of these diets contains any vitamin C. The levels of calcium, phosphorous, magnesium, and vitamin D were 0.82%, 0.53%, 0.25%, and 2.98 IU/g in the 7004 breeder diet and 1.85%, 0.89%, 0.29%, and 5.05 IU/g in the 7001 maintenance diet, respectively. All of the procedures were approved by the Institutional Care and Use Committee of the Jerry L. Pettis Memorial VA Medical Center, Loma Linda, CA.
Bone densitometry by DXA
Total BMC, total body BMD, lean body mass, and percent fat were measured by DXA using the PIXImus instrument (Lunar Corp., Madison, WI, USA). Areal BMD (aBMD) of the femora, tibias, and spine were also measured using the PIXImus instrument. The precision for BMC and BMD was ±1% for repeat measurements of the same bones. (16) 
Dynamic histomorphometry
Histomorphometry was performed on samples from mice at 5 weeks of age. Mice were injected with calcein (20 mg/kg body weight) 8 and 2 days before death for sample collection. The femora were defleshed and embedded in methylmethacrylate. Thick cross-sections (0.5 mm thickness) were cut from the midpoint of the shaft and processed as described. (17) All bone histomorphometric parameters were measured with the OsteoMeasure system equipped with a digitizing tablet (OsteoMetrics, Atlanta, GA, USA) and a color video camera (Sony Corp.) as described. (17) Histomorphometric indices were based on nomenclature recommended by the American Society of Bone and Mineral Research. (18) Biochemical assays Serum osteocalcin levels were measured using a radioimmunoassay (RIA) validated for measuring mouse osteocalcin. (19) The sensitivity of the assay is 0.5 ng/ml. The interand intra-assay CVs are <8%. Serum levels of ascorbic acid were determined using the Roche Diagnostic kit (Roche Diagnostics, Branchburg, NJ, USA).
Genotyping
Genomic DNA was isolated from tail clips using mouse DNAeasy kits (Qiagen, Valencia, CA, USA). DNA samples were quantified and quality determined by measuring their absorbance at 260 and 280 nm. Genotyping was performed using selected microsatellite markers in chromosome 14. PCR reactions and running conditions allowed multiplexing of three to four microsatellite markers in a single electrophoretic lane. The pooled products were analyzed for fragment size on an ABI Model 3100 DNA Analyzer, and GeneScan software was used to size alleles (Applied Biosystems, Foster City, CA, USA). Allele calls and edits were performed using Genotyper software (Applied Biosystems).
PCR amplification of genomic DNA from control and sfx mice with appropriate primer sets was carried out using standard procedures.
RNA extraction
The Qiagen lipid extraction kit was used to extract RNA from bones with the following modification. After the death of the mice, bones were transferred to liquid nitrogen immediately and stored at −80°C until RNA extraction. Bones were ground into a fine powder using mortar and pestle with liquid nitrogen, and extracted with 1 ml of Trizol. RNA was precipitated with chloroform, solubilized in ethanol, and purified according to the instructions provided in the Qiagen kit. RNA extraction from soft tissues was performed using standard procedures. Quality and quantity of RNA were analyzed using a Bio-analyzer (Agilent Technologies, Westlake Village, CA, USA) and a Nano-drop instrument (Ambion, Austin, TX, USA).
Microarray analysis
An aliquot of 500 ng total RNA extracted from bones of control and sfx mice was reverse transcribed using a low RNA amplification and labeling kit and hybridized to a 20,000 mouse development oligo microarray purchased from Agilent. After hybridization, the slide was washed, dried, and scanned using an Agilent scanner. The images were analyzed using Resolver software and signal data were output together with the Agilent probe name, GenBank identification number, and gene description to a Microsoft Excel data spreadsheet. Any significant differences in mRNA intensities were determined by comparing intensities of control and sfx groups by Student's t-test.
Real-time PCR
Quantitation of mRNA expression was carried out by the SYBR green method on a 7900 sequence detection system (ABI PRISM) as recommended by the manufacturer. The data were analyzed using SDS software version 2. Data normalization was accomplished using the endogenous control gene ( 
Nodule assay
Bone marrow cells were expelled from the femoral diaphysis with ␣-MEM using a syringe fitted with a 23-G needle. Cell suspension was counted with a hemocytometer. Subsequently, the bone marrow cells were plated at a density of 7 × 10 6 cells/90-mm per plastic tissue culture dish in ␣-MEM containing 10% calf serum, 100 U/ml penicillin, and 100 g/ml streptomycin. Culture media were changed every 2 days for 6 days and then switched to mineralization media by adding 50 g/ml ascorbic acid and 10 mM ␤-glycerophosphate. Additional 300 g/ml ascorbic acid 2-phosphate was added to some sfx cultures. One-half of the media was changed every 3 days for 30 days. The mineralized matrix was stained for calcium by alizarin red staining method as described. (20) Briefly, after 30 days, cells were washed with PBS, followed by fixation in ice cold 70% ethanol for at least 1 h. Ethanol was removed, and cells were rinsed with water and stained with 40 mM alizarin red (pH 4.2) for 10 minutes at room temperature. Stained cells were further processed by five rinses with water, followed by a 15-minute wash in PBS with rotation to reduce nonspecific alizarin red stain. The mineralized area was measured with the OsteoMeasure system equipped with a digitizing tablet and a color video camera, as previously described.
For gene expression studies, bone marrow cells derived from sfx mice were plated in DMEM, which contained no ascorbic acid, and treated with vehicle or long acting ascorbic acid 2-phosphate (300 g/ml). At various times after treatment, RNA was extracted and used for real-time PCR analyses using primers designed according to the instructions provided by Applied Biosystems. Conditioned media samples were collected and used for measurement of osteocalcin levels as described (19) 
Statistical analysis
Data are presented as means ± SD and analyzed by Student's t-test or ANOVA as appropriate. One-and two-way ANOVA tests were performed using STATISTICA software (Statsoft, Tulsa, OK, USA).
RESULTS
sfx phenotype manifests after weaning
To better characterize the age dependence of the sfx phenotype, we measured musculoskeletal parameters by DXA using PIXImus in sfx/sfx mice and corresponding littermate
VITAMIN C DEFICIENCY CAUSES SPONTANEOUS BONE FRACTURES
control +/? mice longitudinally. Table 1 shows that neither body weight nor any of the musculoskeletal parameters measured were significantly different in the sfx/sfx mice compared with the +/? mice at 21 days of age. However, body weight, lean body mass, BMC, and BMD of the total body and the femur were significantly less in the sfx/sfx mice compared with the +/? mice at 28 days of age. By 35 days of age, both body weight and lean body mass (LBM) were nearly 50% lower in the sfx/sfx mice compared with the +/? mice. Total body BMC and femur BMC were reduced by 25% and 45%, respectively, in the sfx/sfx mice compared with the +/? mice (Table 1) . Accordingly, total body BMD and femur BMD were 12% and 27% lower in the sfx/sfx mice compared with the +/? mice. Whereas BMD of the tibia was decreased by 36%, BMD of the lumbar vertebra was decreased by only 5% in the sfx/sfx mice compared with the +/? mice. The percent fat was not decreased in the sfx/sfx mice compared with the +/? mice. These data show that the phenotype of the sfx mouse manifests itself principally during the period between weaning and attainment of sexual maturity and that bone deficits are more frequent and severe in long bones compared with other bones.
In our study, spontaneous fractures of the femur were identified in both male and female sfx/sfx mice. Radiographs revealed numerous fractures of the femoral metaphysis where the diaphyseal shaft was dislocated and driven into the distal metaphysis in mice 6-7 weeks of age (Fig. 1 ). Fractures were also identified in the radiographs of smaller bones, such as the metacarpals (data not shown).
The mechanism behind the significantly reduced BMD was studied by measuring serum osteocalcin levels and performing dynamic histomorphometry. Serum osteocalcin levels were decreased by 70% in the sfx/sfx mice compared with the +/? mice (62.4 ± 32 versus 198 ± 64 ng/ml; n ‫ס‬ 8, p < 0.001), suggesting a decrease in total osteoblast activity. Histomorphometry at the femoral mid-diaphysis revealed that bone area was decreased by 40% in the sfx/sfx mice compared with control mice (Table 2 ). To avoid fracture callus, histomorphometric analyses were carried out at the mid-diaphysis where there were no fractures. In addition, we killed mice at 5 weeks of age, before they developed fractures. Periosteal and endosteal perimeters were decreased by 13% and 11%, respectively, in the sfx/sfx mice compared with the +/? mice. Notably, the bone formation rate at the periosteum was strikingly compromised by >90% in the sfx/sfx mice, indicating a decrease in total osteoblastic activity. Furthermore, the periosteal mineral apposition rate was decreased by 80% in the sfx/sfx mice, implying an impaired differentiation and/or function of osteoblasts as the major cause for decreased bone formation. There was no detectable label at the endosteum of the sfx/ sfx mice, implying that little or no bone formation occurs at the endosteum of the sfx/sfx mice. Accordingly, it was previously observed that the bones of sfx mice had reduced osteoid but normal osteoclasts. (6) Thus, based on the histomorphometric data, it can be concluded that an impairment of differentiated function of osteoblasts is the major cause for decreased bone formation in sfx/sfx mice.
Fine mapping and identification of the sfx candidate gene
In a previous study, it was shown that the sfx mutation is inherited as a recessive gene that maps to the middle of chromosome 14. (6) We mapped the region previously shown to contain the sfx locus more precisely by genotyping additional markers in this region. Table 3 shows the results of our haplotype analysis of 272 Balb/cBy-Cast F2 sfx/sfx mice for six markers near the sfx locus. No recombination between the sfx gene and D14Mit203 was detected in 272 sfx/sfx mice. In two mice, there were triple recombinations, with one recombination after D14Mit66 and two recombinations, one on each side of D14Mit203, which were confirmed by repeated genotyping. Based on these data, we concluded that the sfx gene was located near the D14Mit203 marker on chromosome 14, between 56.04 and 58.20 MB (NCBI database) or between 58.82 and 60.96 MB (Celera database). This 2-MB region contains ∼30 genes based on the predicted genes in the Celera database (Table  4 ). There were several potential candidate genes, such as Hox-related protein, exostosin-3 related, Frizzled 3, and Fbox only protein 16 , that were located within the 2-MB sfx region. We initially sequenced the coding regions of these positional candidate genes and found no evidence for mutation in the coding region in them (Table 4) .
We next performed a whole genome microarray analysis using 20,000 mouse oligonucleotide probes (Agilent) to identify genes differentially expressed in the bones of sfx and control mice. We reasoned that information on the molecular pathways affected in the bones of sfx mice would provide some knowledge on the potential candidate genes for sfx. Although several genes in the sfx locus were present in the microarray slide, we found none of these genes showed a significant change in expression in the bones of the sfx mice compared with control mice. Whole genome microarray analysis did, however, reveal that the expression of several genes related to mitochondrial energy metabolism was severely compromised in the bones of sfx mice compared with control mice (data not shown). Particularly, we found that the expression levels of a number of ATPases (Atpla3, Atp2c1, Atp5k, Atp5j, Atp5j2, Atp5g3, and Atp51) were significantly altered in the bones of sfx mice compared with control mice (data not shown).
To identify potential candidate genes in the sfx locus that could be involved in regulating energy metabolism, we searched for functional motifs in the 30 genes present near the sfx locus using the ScanProsite tool (Swiss Institute of Bioinformatics). This search led to the identification of two candidate genes, mCG141014 (mCT 172717) and mCG2517 (mCT 1325), which were located at 60.34 and 60.73 MB, respectively, in chromosome 14 (Celera database). The sequence analysis of the coding region of the mCG141014 gene (similar to hypothetical protein XP_154842.1), which contains a ATP/GTP binding site (P-loop motif), revealed no sequence polymorphisms between the sfx and control mice (Table 4) . We next focused on the second candidate gene, mCG2517, which encoded a hypothetical protein (BC019856) similar to GULO, an enzyme involved in the synthesis of ascorbic acid. Because the expression levels of several dehydrogenases were altered in the sfx mice and because mCG2517 contained a FAD binding site, we considered this gene a strong candidate for sfx. To sequence the coding region of mCG2517, we amplified the coding region using exon-specific primers and cDNA prepared from bones of control and sfx mice as templates (Table 5) .
To our surprise, we were able to amplify PCR products for cDNA from the control mice, but not the sfx mice, using a number of primers in the coding region of GULO ( Fig.  2A) . The six primer sets used for evaluation of GULO expression covered the entire coding region of the GULO This gene list was prepared according to Celera database. mCT numbers represent transcript numbers for various genes provided in the Celera database. The location of genes in chromosome 14 is based on information provided by the Celera database. No product could be amplified for mCT 155292, mCT 126977, mCT 1333, and mCT 1327 using cDNA prepared using RNA from bone.
ND, not determined.
sequence (BC019856.1) as shown in 
Mapping of GULO deletion in sfx mice
To confirm and examine the extent of chromosomal deletion in our sfx mice, we used DNA isolated from sfx/sfx and +/? control mice to amplify the 5Ј end, intronic, and 3Ј end of GULO using appropriate primers throughout the GULO gene (Table 6 ). The transcribed region of the GULO gene resides in chromosome 14 between 57,994,797 and 57,972,426 bp (encodes mRNA BC019856.1; http:// genome.ucsc.edu). Consistent with the data using cDNA from bones, PCR amplification of genomic DNA from sfx mice failed to generate PCR products for primers located within the transcribed region of the GULO gene (Table 6 ; Fig. 2B ). These data provide evidence that the transcribed region of the GULO gene is deleted in the sfx mice. To identify the extent of chromosome 14 deletion, we designed additional primers at both 5Ј and 3Ј ends of the GULO gene and generated PCR products using DNA from control and sfx mice (Table 6 ; Fig. 2B ). Our first sets of primers were ∼3000 bp apart at both the 5Ј and 3Ј ends of the transcribed region of the GULO gene. Subsequently, we refined the deletion more precisely by designing additional primers in the region of interest. Using this strategy, we determined that the deletion occurs after 58,008,985 bp and before 57,970,574 bp at the 5Ј and 3Ј ends of the transcribed region of the GULO gene, respectively (Table 6 ; Fig. 2B ). To determine if the chromosomal deletion in sfx mice extended to the neighboring genes, we designed a number of PCR primers for the transcribed region of genes, Adam 2 and C130058N24Rik, that were located upstream or downstream, respectively, of the GULO gene in chromosome 14. We were able to amplify PCR products of anticipated size using DNA from both sfx and control mice for both of these genes (data not shown), indicating that the deletion was confined to the GULO gene in sfx mice.
To identify the exact location of deletions in chromosome 14 in the sfx mice, we generated PCR products using GULO 5Ј-2A forward primer and 3Ј-1A reverse primer (Table 6 ). Figure 2C shows the results of PCR amplification of DNA from +/+, +/sfx, and sfx/sfx mice. A PCR product of ∼700 bp was amplified using DNA from sfx/+ and sfx/sfx mice but not +/+ mice (product was too large to amplify because there was no deletion). We sequenced the amplified product to identify the exact location of deletion. BLAT search of mouse genome (http://genome.ucsc.edu) using nucleotide sequence of PCR product from sfx mice revealed 100% alignment with 58,009,113 to 58,008,747 bp and with 57,970,600 to 57,970,381 bp of mouse genome sequence in chromosome 14. Based on the sequence information and the PCR data, we determined that a 38,146-bp region encompassing 58,008,746 to 57,970,601 bp of chromosome 14 containing the entire transcribed region of the GULO gene is deleted in sfx mice (Fig. 2D) . Because the deleted region in chromosome 14 does not contain any other predicted genes and because there was no polymorphism in the coding region of other potential candidate genes in the sfx locus (Table 4) , we concluded that GULO is the sfx gene.
To further confirm the deletion of GULO in sfx mice, we performed PCR amplification of GULO using DNA from several inbred strains of mice and found that GULO is only absent in sfx mice and present in all other stains of mice we tested (data not shown). Surprisingly, Agilent microarray data revealed no difference in expression levels of GULO Primers were designed along the entire coding region of GULO (BC019856.1). The corresponding regions of mRNA sequence amplified by different overlapping primer sets were identified by Contig Express (Vector NTI, InfoMax, Bethesda, MD, USA). All six primer sets failed to produce PCR products using cDNA prepared from bones of sfx/sfx mice. However, PCR products of anticipated size could be produced using cDNA from the bones of +/? mice as a template. cDNA prepared from four to six sfx/sfx and corresponding control mice were used as templates for PCR amplification. The results were confirmed in at least one duplicate experiment.
These data show that GULO transcript is absent in sfx/sfx mice. +, PCR product of right size was amplified; −, no PCR product could be amplified.
between the bones of the control and sfx mice. The 60-mer oligo probe used in the Agilent microarray falls within the deleted region of chromosome 14 in sfx mice (57,973,026-57,972,967 bp). Accordingly, our GULO coding primer set that amplified a region from 57,973,204 to 57,972,817 bp was positive for cDNA from control mice and negative for cDNA for sfx mice. To determine whether the GULO oligo probe used in the Agilent microarray cross-hybridized with one or more transcripts expressed in bone and contributed to the apparent discrepancy, we performed a NCBI BLAST search (http://www.ncbi.nim.nih.gov/BLAST) and found no significant cross-reactivity with other mouse transcripts besides GULO. It is therefore unclear why the sfx mice have measurable mRNA for the GULO gene by Agilent microarray.
Ascorbic acid deficiency in sfx mice
If our prediction that the entire transcribed region of the GULO gene is deleted in chromosome 14 is correct, sfx mice should be deficient in ascorbic acid. Therefore, we measured serum ascorbic acid levels in sfx and corresponding control mice. Figure 3 shows there was no detectable level of ascorbic acid in the sfx/sfx mice, whereas control mice showed the expected levels of ascorbic acid in their blood. The lack of ascorbic acid in the serum of 6-week-old sfx mice is not surprising because the diet we used contained no vitamin C.
Reversal of sfx phenotype by treatment of sfx/sfx mice with ascorbic acid
If deletion of GULO is responsible for the sfx phenotype, it follows that we should be able to correct the phenotype by giving ascorbic acid to sfx/sfx mice. To obtain further proof that GULO is the sfx gene, we treated sfx/sfx mice with ascorbic acid in their drinking water (330 mg/liter). Figure 4 shows that treatment of sfx/sfx mice at weaning with ascorbic acid for 3 weeks led to a reversal of the sfx
FIG. 2.
(A) PCR amplification of GULO coding region using cDNA from bones of control and sfx mice; 200 ng of RNA isolated from bones of +/? and sfx/sfx mice was used for preparation of cDNA. An aliquot of cDNA was used for PCR amplification using primers that cover the entire coding region of GULO (Table 5 ). PCR products of anticipated size were amplified for cDNA from control mice but not for cDNA from sfx mice. C, control mice; S, sfx/sfx mice. (B) PCR amplification of DNA using various primers; 20 ng of DNA isolated from spleen of +/? and sfx/sfx mice was used for PCR amplification using various sets of primers in the 5ЈUTR, intronic, and 3ЈUTR regions of GULO. The sequence of primers used and the region of chromosome 14 amplified by the various primers are shown in Table 6 . PCR products of only selected primers are shown for the sake of space. No PCR product was seen for chromosomal region encompassing 58,008,858-57,971,069 bp using DNA from sfx/sfx mice. (C) PCR amplification of DNA using sfx/sfx, sfx/+, and +/+ mice with chromosome 14 forward primer (58,009,161-58,009,182 bp) and reverse primer (57,970,352-57,970,371 bp). Wildtype (+/+), heterozygous (sfx/+), and sfx (sfx/sfx) mice were identified by genotyping using two sets of primers. ALP gene was used as an internal control. GULO intron1 primer set in the transcribed region of GULO-amplified PCR product of anticipated size for DNA from both wildtype and heterozygous mice but not for sfx mice. Forward primer for GULO 5Ј-2A and reverse primer for GULO 3Ј1A, which are located at the 5Ј and 3Ј ends of chromosome 14, deletion in sfx mice amplified PCR product of ∼700 bp for both sfx homozygous and heterozygous mice but not for wildtype mice. Heterozygous mice have one copy of intact and one copy of deleted chromosome 14 and are therefore positive for both sets of primers. sfx homozygous mice have both copies of deleted chromosomes and are therefore negative for GULO intron 1 primer set but positive for GULO 5Ј-2A forward/GULO 3Ј-1A reverse primer set. Wildtype mice have both copies of intact chromosome 14 and are therefore positive for GULO intron 1 primer set and negative for GULO 5Ј-2A forward/GULO 3Ј-1A reverse primer set, because the product is too large to amplify. The PCR product from sfx/sfx homozygous mice was used for sequencing. (D) Map of deletion in chromosome 14 in sfx mice. The sequence of PCR product amplified using GULO 5Ј-2A forward and GULO 3Ј-1A reverse primer set was BLAT searched to identify matching a sequence in mouse chromosome 14. The nucleotide sequence of PCR product revealed a 100% sequence identity with a 58,009,113-58,008,747-bp segment and a 57,970,600-57,970,381-bp segment of mouse chromosome 14. Based on these data, we have mapped the deletion to a region between 58,008,747 and 57,970,600 bp (38,146 bp) in chromosome 14 reverse strand. Box labeled GULO represents the transcribed region of GULO. The position of the PCR primers included in Table 6 are shown here as thick black lines.
phenotype to near normal levels for both the body weight and musculoskeletal parameters that we studied. The homozygous sfx/sfx mice treated with ascorbic acid grew normally during puberty and acquired bone mass comparable with that of corresponding control mice fed with a similar amount of ascorbic acid. Whereas treatment of sfx mice with ascorbic acid corrected the musculoskeletal deficits, Different primer sets were used to amplify various regions of the GULO gene. The corresponding regions of genomic sequence amplified in chromosome 14 were identified by BLAT search of mouse genome sequence (http://genome.ucsc.edu). The DNA from four to six sfx/sfx and corresponding control mice were used for evaluation. The results were confirmed in at least one independent experiment. Only informative primers tested are listed for the sake of space.
These data show that the region between 58,008,858 and 57,971,069 bp could not be amplified using DNA from sfx mice. +, PCR product of right size was amplified; −, no PCR product could be amplified.
FIG. 3.
Serum levels of ascorbic acid in sfx/sfx and corresponding sfx/? control mice. Serum from 6-week-old sfx/sfx and corresponding control mice were used for measurement of ascorbic acid by a commercial kit. Values are mean ± SD of five mice per group.
A p < 0.001 vs. control mice. Ascorbic acid levels were undetectable in sfx/sfx mice.
FIG. 4.
Effects of ascorbic acid treatment on the musculoskeletal parameters in sfx mice. Sfx/sfx and +/? mice were given ascorbic acid in the drinking water (330 g/ml), and the water was changed every other day. Control mice were given drinking water without ascorbic acid. Ascorbic acid treatment began at 3 weeks of age, the animals were killed at 6 weeks of age, and musculoskeletal parameters were measured by PIXImus. Control and sfx/sfx mice receiving drinking water were killed at 5 weeks of age because fractures start to occur at 5 weeks in sfx/sfx. Values are percent corresponding control (+/?) mice treated with or without ascorbic acid and are mean ± SD of eight mice per group. Ascorbic acid treatment fully corrected the sfx phenotype. , suggesting that the endogenously produced vitamin C was adequate for normal growth in the control mice. Furthermore, the sfx/sfx mice fed with ascorbic acid in their drinking water were fertile, showed no evidence of fractures, and produced normal sized litters (8.9 ± 2.1 versus 9.8 ± 1.7 offspring/litter, n ‫ס‬ 10 litters). We currently have several of the sfx/sfx mice fed with ascorbic acid that are >6 months old and exhibit no signs of scurvy or other features of sfx phenotype. These data provide convincing evidence that a deficiency in ascorbic acid caused by a disruption of the GULO gene contributes to the observed phenotype in the sfx mice.
GULO is expressed in a number of tissues
To examine if GULO is involved in regulating local production of ascorbic acid in various cell types, we evaluated expression levels of GULO in various tissues by real-time PCR. Accordingly, we found evidence for expression of GULO in a number of tissues, including liver, adrenal gland, muscle, bone, kidney, brain, thymus, and spleen ( Table 7 ). The magnitude of GULO expression is >20-fold higher in the liver than in a number of other tissues, suggesting that the liver is the major endocrine source of ascorbic acid in blood. Because the magnitude of GULO expression in various tissues did not seem to correlate with the severity of phenotype, the extent to which the local production of ascorbic acid contributes to regulating the differentiated functions of cell types in various tissues remains to be determined.
Impaired osteoblast differentiation in sfx phenotype is corrected by ascorbic acid treatment
We next sought to determine if the deficiency in bone formation in sfx/sfx mice is caused by impairment in the formation of mature osteoblasts. To this end, we cultured bone marrow stromal cells from sfx/sfx and +/? mice and examined the ability of these cells to form mineralized nodules in vitro. Figure 5A shows that bone marrow stromal cells from sfx/sfx mice produced very few or no mineralized nodules when grown in mineralization medium containing 50 g/ml ascorbic acid. However, treatment of bone marrow stromal cells from sfx/sfx mice with 300 g/ml ascorbic acid 2-phosphate, a long acting vitamin C derivative, (21) led to a reversal of mineralization defects. The percentage of mineralized nodule area was 0.29 ± 0.2% and 10.5 ± 4.8% (SD; n ‫ס‬ 3, p < 0.05), respectively, in bone marrow cultures derived from sfx and wildtype mice cultured in mineralization media. Addition of 300 g/ml ascorbic acid 2-phosphate to bone marrow cells derived from sfx mice increased the mineralized area by 30-fold (8.9 ± 4.2%, p < 0.05 versus mineralization media). Furthermore, we found that ascorbic acid treatment of bone marrow stromal cells from sfx mice for 12 days increased expression levels of type I collagen, alkaline phosphatase (ALP), and osteocalcin by 6-, 8-, and 20-fold, respectively, (p < 0.001) compared with cells cultured without ascorbic acid (Fig. 5B) . Figure 5C shows that osteocalcin levels were undetectable in the conditioned medium of bone marrow stromal cells derived from sfx/sfx mice cultured for 24 days in DMEM that contained no ascorbic acid. Treatment of bone marrow stromal cells from sfx mice with 300 g/ml ascorbic acid 2-phosphate increased osteocalcin levels by >50-fold at day 24. These and other in vitro data (21) (22) (23) provide convincing evidence that ascorbic acid is an important regulator of differentiated functions of osteoblasts.
DISCUSSION
We have provided several very strong lines of evidence that the GULO gene is the sfx gene. The importance of the sfx gene in skeletal biology is underscored by the fact that only a select few genetic abnormalities lead to spontaneous fracture at a young age. If the sfx phenotype is caused exclusively by a deficiency in vitamin C resulting from a deletion of the GULO gene, it stands that the sfx phenotype should be completely reversed by supplemental administration of vitamin C, as was found in our study. Furthermore, the in vitro phenotype (i.e., impairment in the differentiation of bone marrow stromal cells into osteoblasts) was as dramatic as the fracture phenotype in vivo and was also rescued by vitamin C treatment.
In addition to creating these dramatic skeletal phenotypes, vitamin C deficiency also causes widespread abnormalities in multiple organs. In this regard, the epidemiology of scurvy or vitamin C deficiency has differed from the past to present. During the 15th and 17th centuries, scurvy emerged as a problem for maritime explorers when it was a fatal disease among sailors. The symptoms and signs of patients with vitamin C deficiency included inability to walk, tenderness in lower limbs, subperiosteal bleeding, gum hypertrophy and bleeding, and anemia. (7) (8) (9) (10) The most common cutaneous findings are follicular hyperkeratosis, perifollicular hemorrhages, ecchymoses, xerosis, leg edema, poor wound healing, and bent or coiled body hairs. (7) Although scurvy is currently uncommon because of food fortification with vitamin C, the disease occasionally occurs in some parts of the world among refugees and children fed improperly by their parents. (7) (8) (9) (10) We found that sfx mice exhibited several features common to scurvy. For example, sfx mice exhibit significantly reduced body size, thymus, and spleen weights, as well as lower red and white blood cell counts, compared with age-matched control mice. (6) Based on our observations that sfx mice exhibit symptoms of scurvy syndrome, as well as documented observations in other studies, (24, 25) we maintain that vitamin C deficiency can affect nearly every organ in the body. With regard to future studies, the bone phenotype is readily quantifiable and serves as an effective model for evaluating the effects of vitamin C deficiency on the body. In addition, if other cell types behave similarly to bone cells, then one would expect a generalized impairment in cell differentiation in response to ascorbic acid deficiency, which can be readily studied using osteoblasts in vitro.
The terminal step in the biosynthesis of l-ascorbic acid in mammals is dependent on GULO (EC 1.1.3.8), which is present in several mammalian species, including mice, rats, and pigs, but not in humans. (26) In previous studies, it was found that a particular strain of rat, the osteogenic disorder rat (ODS rat), developed signs characteristic of a vitamin C-deficient animal, including bleeding tendencies, skeletal abnormalities, and reduced GULO activity. (27, 28) In the ODS rat, an A-G transition leads to a 61Cys-61Tyr substitution, which is responsible for the dramatic reduction in GULO enzyme activity. (29) More recently, Maeda et al. (30) generated a vitamin C-deficient (GULO
−/−
) mouse strain by deleting exons III and IV through homologous recombination and found aortic wall damage in mice lacking functional GULO. In these studies, it was observed that the body weights of homozygous pups born to heterozygous mothers showed no variation at 21 days of age from their littermate controls. However, after weaning onto regular chow containing 110 mg/kg of ascorbic acid, the homozygotes showed very little growth, and after 40 days of age, they began to lose weight. We believe that the phenotype is more severe in the sfx mice because the laboratory chow used in our study contained no vitamin C.
Our data that heterozygous mice grow normally suggest Effects of ascorbic acid treatment on osteocalcin levels in conditioned medium of bone marrow cells derived from sfx/sfx mice. Cells were cultured in DMEM containing 10% calf serum as described for B and treated with vehicle or 300 g/ml ascorbic acid 2-phosphate. At days 6, 12, 18, and 24, conditioned medium was collected and used for osteocalcin measurements. Values are mean ± SD of six replicate cultures. Osteocalcin levels were below detection limit (<1.56 g/ml) in vehicle-treated bone marrow cells. p < 0.001 in ascorbic acid treated cultures vs. control.
that a single copy of GULO is sufficient to produce adequate levels of ascorbic acid for normal growth in mice. The reason why the sfx/sfx mice grow normally until they are weaned is likely because of the presence of ascorbic acid in high concentrations in the mothers' milk. (13) On weaning, the sfx/sfx mice are completely deprived of ascorbic acid because the laboratory chow used in this study does not contain ascorbic acid. The lack of ascorbic acid during the pubertal rapid growth phase leads to little or no new bone formation, and as a consequence, fractures occur.
Although the observation that ascorbate deficiency led to diminished ALP in mineralized tissues was first published over 50 years ago, (31) the molecular pathways by which ascorbic acid deficiency leads to impaired bone formation are still poorly understood. In this regard, the most welldocumented effect of ascorbate is on hydroxylation of prolyl and lysyl residues, which are necessary for the formation of stable triple helical collagen. (32) Several laboratories have shown that treatment of osteoblasts with ascorbic acid increased expression of specific genes associated with the osteoblast phenotype, including type I collagen, ALP, and osteocalcin. (22, (33) (34) (35) With regard to the question of how ascorbic acid promotes transcriptional activity of genes, Xiao et al. (36) have shown that ascorbic acid treatment stimulates promoter activity of the osteocalcin gene by upregulating the binding of osteoblast-specific factor 2 to an osteoblast-specific element in the promoter region. Thus, one way ascorbic acid treatment may promote differentiation is by activating the transcription of key genes involved in producing extracellular matrix proteins. A number of alternate mechanisms have been proposed to explain the mechanism by which ascorbic acid stimulates expression of bone formation marker genes, which include ascorbic acid-induced alterations in extracellular matrix and changes in the availability of IGF-I, extracellular calcium, or ATP. (37) (38) (39) It is well established that ascorbic acid is necessary for the in vitro differentiation of osteoblasts. (22, (33) (34) (35) (40) (41) (42) The ability of ascorbic acid to promote differentiation is not specific to osteoblasts, because studies have shown that ascorbic acid also induces differentiation in a variety of cell types including myoblasts, adipocytes, and chondrocytes. (43) (44) (45) More recently, ascorbic acid has been shown to enhance differentiation of embryonic stem cells into cardiac myocytes. (46) Furthermore, Yu et al. (47) have recently shown that treatment of mesencephalic precursor cells with ascorbic acid increases their differentiation into dopaminergic neurons. Consistent with these in vitro data, our findings provide the first genetic evidence for an important role for ascorbic acid in regulating differentiated functions of osteoblasts in vivo. Our future studies will address the molecular mechanisms by which ascorbic acid deficiency regulates differentiated cell function using osteoblasts derived from sfx mice as our model. Surprisingly, bone accretion is compromised much more in the long bones of sfx mice compared with vertebrae. Accordingly, the magnitude of total body BMD (excluding calvaria) deficit is less compared with femur or tibia BMD deficit in the sfx mice. At present, we have no experimental data to provide an explanation for the differential effects of ascorbic acid deficiency in the long bones versus vertebrae.
Although these findings are based on studies using a mouse model, we believe that the findings of this study have strong clinical implications. It is well known that humans depend on their diet for vitamin C because they lack the GULO gene and therefore cannot synthesize vitamin C. Based on our data that sfx mice with a complete deficiency in vitamin C form very little new bone, we believe that adequate vitamin C intake during the early active growth period may be critical in attaining an optimal peak BMD in humans as well. Furthermore, these findings also indicate that vitamin C deficiency may play a critical role in some of the skeletal abnormalities observed in the elderly, a segment of the population particularly susceptible to malnourishment. In fact, clinical epidemiological studies support this view. (48) (49) (50) Finally, in light of these findings, it is possible that a subclinical vitamin C deficiency impairs skeletal development during puberty. Further studies are needed to evaluate the extent to which vitamin C deficiency may contribute to the development of peak BMD during puberty and to the decline in osseous tissue during aging.
